vs
Side-by-side financial comparison of Maplebear Inc. (CART) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $992.0M, roughly 1.1× Maplebear Inc.). Hologic runs the higher net margin — 17.1% vs 8.2%, a 8.9% gap on every dollar of revenue. On growth, Maplebear Inc. posted the faster year-over-year revenue change (12.3% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $171.0M). Over the past eight quarters, Maplebear Inc.'s revenue compounded faster (10.0% CAGR vs 1.5%).
Maplebear Inc., doing business as Instacart, is an American retail media and delivery company based in San Francisco that operates a grocery delivery and pick-up service in the United States and Canada accessible via a website and mobile app. It allows customers to order groceries, and alcohol where legal, from participating retailers with the shopping being done by a personal shopper, who picks, packs, and delivers the order.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
CART vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $992.0M | $1.0B |
| Net Profit | $81.0M | $179.1M |
| Gross Margin | 72.3% | 56.0% |
| Operating Margin | 9.9% | 22.6% |
| Net Margin | 8.2% | 17.1% |
| Revenue YoY | 12.3% | 2.5% |
| Net Profit YoY | -45.3% | -10.9% |
| EPS (diluted) | $0.31 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $992.0M | $1.0B | ||
| Q3 25 | $939.0M | $1.0B | ||
| Q2 25 | $914.0M | $1.0B | ||
| Q1 25 | $897.0M | $1.0B | ||
| Q4 24 | $883.0M | $1.0B | ||
| Q3 24 | $852.0M | $988.0M | ||
| Q2 24 | $823.0M | $1.0B | ||
| Q1 24 | $820.0M | $1.0B |
| Q4 25 | $81.0M | $179.1M | ||
| Q3 25 | $144.0M | $187.2M | ||
| Q2 25 | $116.0M | $194.9M | ||
| Q1 25 | $106.0M | $-17.4M | ||
| Q4 24 | $148.0M | $201.0M | ||
| Q3 24 | $118.0M | $178.6M | ||
| Q2 24 | $61.0M | $194.5M | ||
| Q1 24 | $130.0M | $169.9M |
| Q4 25 | 72.3% | 56.0% | ||
| Q3 25 | 73.7% | 55.6% | ||
| Q2 25 | 74.2% | 56.3% | ||
| Q1 25 | 74.8% | 37.5% | ||
| Q4 24 | 75.2% | 56.8% | ||
| Q3 24 | 75.2% | 56.4% | ||
| Q2 24 | 75.7% | 55.4% | ||
| Q1 24 | 74.9% | 53.3% |
| Q4 25 | 9.9% | 22.6% | ||
| Q3 25 | 17.7% | 22.6% | ||
| Q2 25 | 13.6% | 24.9% | ||
| Q1 25 | 12.3% | -0.7% | ||
| Q4 24 | 17.6% | 22.5% | ||
| Q3 24 | 16.2% | 23.3% | ||
| Q2 24 | 6.3% | 24.1% | ||
| Q1 24 | 17.6% | 20.7% |
| Q4 25 | 8.2% | 17.1% | ||
| Q3 25 | 15.3% | 17.8% | ||
| Q2 25 | 12.7% | 19.0% | ||
| Q1 25 | 11.8% | -1.7% | ||
| Q4 24 | 16.8% | 19.7% | ||
| Q3 24 | 13.8% | 18.1% | ||
| Q2 24 | 7.4% | 19.2% | ||
| Q1 24 | 15.9% | 16.7% |
| Q4 25 | $0.31 | $0.79 | ||
| Q3 25 | $0.51 | $0.84 | ||
| Q2 25 | $0.41 | $0.86 | ||
| Q1 25 | $0.37 | $-0.08 | ||
| Q4 24 | $0.53 | $0.87 | ||
| Q3 24 | $0.42 | $0.75 | ||
| Q2 24 | $0.20 | $0.82 | ||
| Q1 24 | $0.43 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $687.0M | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $2.5B | $5.2B |
| Total Assets | $3.7B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $687.0M | $2.4B | ||
| Q3 25 | $1.7B | $2.2B | ||
| Q2 25 | $1.6B | $1.9B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.3B | $2.3B | ||
| Q2 24 | $1.4B | $2.4B | ||
| Q1 24 | $1.5B | $2.2B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | $2.5B | $5.2B | ||
| Q3 25 | $3.5B | $5.0B | ||
| Q2 25 | $3.3B | $4.8B | ||
| Q1 25 | $3.2B | $4.6B | ||
| Q4 24 | $3.1B | $4.8B | ||
| Q3 24 | $2.9B | $5.1B | ||
| Q2 24 | $3.0B | $5.0B | ||
| Q1 24 | $3.1B | $4.8B |
| Q4 25 | $3.7B | $9.2B | ||
| Q3 25 | $4.5B | $9.0B | ||
| Q2 25 | $4.4B | $8.8B | ||
| Q1 25 | $4.3B | $8.5B | ||
| Q4 24 | $4.1B | $8.7B | ||
| Q3 24 | $3.9B | $9.2B | ||
| Q2 24 | $4.0B | $8.9B | ||
| Q1 24 | $4.1B | $8.7B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.0M | $229.9M |
| Free Cash FlowOCF − Capex | $171.0M | $215.2M |
| FCF MarginFCF / Revenue | 17.2% | 20.5% |
| Capex IntensityCapex / Revenue | 1.2% | 1.4% |
| Cash ConversionOCF / Net Profit | 2.26× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $910.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.0M | $229.9M | ||
| Q3 25 | $287.0M | $355.1M | ||
| Q2 25 | $203.0M | $343.3M | ||
| Q1 25 | $298.0M | $169.4M | ||
| Q4 24 | $153.0M | $189.3M | ||
| Q3 24 | $185.0M | $367.0M | ||
| Q2 24 | $244.0M | $405.8M | ||
| Q1 24 | $105.0M | $292.4M |
| Q4 25 | $171.0M | $215.2M | ||
| Q3 25 | $272.0M | $341.4M | ||
| Q2 25 | $187.0M | $330.5M | ||
| Q1 25 | $280.0M | $153.9M | ||
| Q4 24 | $141.0M | $172.5M | ||
| Q3 24 | $171.0M | $350.6M | ||
| Q2 24 | $220.0M | $385.3M | ||
| Q1 24 | $91.0M | $279.6M |
| Q4 25 | 17.2% | 20.5% | ||
| Q3 25 | 29.0% | 32.5% | ||
| Q2 25 | 20.5% | 32.3% | ||
| Q1 25 | 31.2% | 15.3% | ||
| Q4 24 | 16.0% | 16.9% | ||
| Q3 24 | 20.1% | 35.5% | ||
| Q2 24 | 26.7% | 38.1% | ||
| Q1 24 | 11.1% | 27.5% |
| Q4 25 | 1.2% | 1.4% | ||
| Q3 25 | 1.6% | 1.3% | ||
| Q2 25 | 1.8% | 1.3% | ||
| Q1 25 | 2.0% | 1.5% | ||
| Q4 24 | 1.4% | 1.6% | ||
| Q3 24 | 1.6% | 1.7% | ||
| Q2 24 | 2.9% | 2.0% | ||
| Q1 24 | 1.7% | 1.3% |
| Q4 25 | 2.26× | 1.28× | ||
| Q3 25 | 1.99× | 1.90× | ||
| Q2 25 | 1.75× | 1.76× | ||
| Q1 25 | 2.81× | — | ||
| Q4 24 | 1.03× | 0.94× | ||
| Q3 24 | 1.57× | 2.05× | ||
| Q2 24 | 4.00× | 2.09× | ||
| Q1 24 | 0.81× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CART
| Transaction | $698.0M | 70% |
| Advertising And Other | $294.0M | 30% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
